Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04672889
Other study ID # 201703031RINC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date December 30, 2024

Study information

Verified date March 2023
Source TCI Co., Ltd.
Contact Ming Shiang Wu, Professor
Phone 23123456
Email mingshaing@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In order to understand the life history of the breast milk flora, explore its composition, source of strains, and ability to colonize the baby's intestinal environment, to find out strains with the potential of probiotics in breast milk


Description:

This is a double-blind and randomized study. After being discharged from the hospital, the subject was notified to consume the Babyguard breast milk probiotic daily for 1 month, and observe whether the mother's stool, breast milk and baby stool samples can find the same strain. The clinical diagnosis items of the bacterial strains of mother feces, breast milk and baby feces samples are evaluated by the doctor.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 30, 2024
Est. primary completion date October 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - At least 20 years old, pregnant women with non-high-risk pregnancy risk assessed by obstetricians and gynecologists, healthy mothers and infants with no abnormal obstetric examination results Exclusion Criteria: - Pregnant women who have used oral or injectable antibiotics within three months before delivery, or women who need a cesarean section for any reason during pregnancy

Study Design


Related Conditions & MeSH terms

  • Dysbiosis
  • Intestinal Bacteria Flora Disturbance

Intervention

Dietary Supplement:
Placebo
consume 1 sachet per day for 1 months
Babyguard® Breast Milk Probiotics
consume 1 sachet per day for 1 months

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei Zhongzheng District

Sponsors (1)

Lead Sponsor Collaborator
TCI Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Microflora of mother's feces Collect mother's feces for bacterial analysis.The mother's feces use Qiagen stool mini kit to extract DNA, and then use the intestinal bacteria primers to detect the presence of intestinal bacteria in the feces. 4-6 weeks after the baby is born
Primary Group. B Streptococcus (GBS) screening Use sterile cotton sticks for vaginal samples, and then perform Group. B Streptococcus (GBS) screening 35-37 weeks of pregnancy
Primary The microflora of maternal blood Use venous blood to collect 20 ml of mother's blood for bacterial analysis.The mother's blood uses Qiagen DNA isolation mini kit to extract DNA, and then uses intestinal bacteria primers to detect the presence of intestinal bacteria in the blood 4-6 weeks after the baby is born
Primary Metabolic analysis of maternal urine Collect 10 ml of mother's urine for intestinal dysbiosis analysis. Use Qiagen DNA isolation mini kit to extract DNA from the mother's urine, and then use the intestinal bacteria primer to detect the presence of intestinal bacteria in the urine. 4-6 weeks after the baby is born
Primary Bacteria analysis of breast milk Collect 10 ml of breast milk for bacterial phase analysis.Use Qiagen DNA isolation mini kit to extract DNA from breast milk, and then use intestinal bacteria primers to detect whether the breast milk contains intestinal bacteria. 4-6 weeks after the baby is born
Primary Bacteria analysis of infant feces Collect baby feces for bacterial phase analysis.Use Baby feces use Qiagen stool mini kit to extract DNA, and then use intestinal bacteria primers to detect the presence of intestinal bacteria in the feces. 4-6 weeks after the baby is born
See also
  Status Clinical Trial Phase
Completed NCT02538211 - The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses N/A
Completed NCT02220439 - Does the Fecal Microbiome Influence Rotarix Immunogenicity N/A
Completed NCT02539836 - Study on Dietary Nutrition Intervention Techniques for Children Obesity N/A
Recruiting NCT05461508 - Fucoidan Assisted Eradication of Helicobacter Pylori Phase 1/Phase 2
Active, not recruiting NCT03667404 - Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study Phase 2
Completed NCT02318134 - Fecal Microbiota Transplantation for Pancreatitis Phase 2
Completed NCT03770143 - Evaluation of the Effect of Palm Olein Free Formula on Intestinal Flora and Gastrointestinal Tolerance
Completed NCT01591538 - Multi-Antibiotic Resistance Carriage in Gut Flora N/A
Completed NCT03103958 - Effects of Probiotic on Modulation of the Intestinal Microbiota in Constipated Patients N/A
Not yet recruiting NCT05658055 - The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication Phase 4
Recruiting NCT03016780 - Fecal Microbiota Transplantation for Ulcerative Colitis Phase 1/Phase 2
Recruiting NCT03018613 - Fecal Microbiota Transplantation for Chronic Functional Constipation Phase 1/Phase 2
Recruiting NCT03015467 - Fecal Microbiota Transplantation (FMT) for Severe Acute Pancreatitis(SAP) Phase 1/Phase 2
Completed NCT05016999 - Allium Extracts on the Intestinal Microbiota in Healthy Resident Volunteers. N/A
Completed NCT02377063 - The Effect of Fruit/Vegetable Drinks on the Human Intestine N/A